Calliditas Announces Positive Data From Proof-of-concept Phase 2 Trial With Setanaxib
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Calliditas Therapeutics (CALT) reported data from the proof-of-concept Phase 2 trial evaluating setanaxib, the company’s lead NOX enzyme inhibitor, in combination with pembrolizumab, in patients with squamous cell carcinoma of the head and neck. The analysis showed st
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2007594509-ba97533a0736449eb4661aa3324f7d5b.jpg "Why Should I Pay Myself First?")